z-logo
open-access-imgOpen Access
Myeloperoxidase Promoter Polymorphism463G Is Associated With More Severe Clinical Expression of Cystic Fibrosis Pulmonary Disease
Author(s) -
Wanda F. Reynolds,
Isabelle SermetGaudelus,
Valérie Gausson,
Marie-Noëlle Feuillet,
JeanPaul Bonnefont,
G. Lenoir,
Béatrice DescampsLatscha,
Véronique WitkoSarsat
Publication year - 2006
Publication title -
mediators of inflammation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.37
H-Index - 97
eISSN - 1466-1861
pISSN - 0962-9351
DOI - 10.1155/mi/2006/36735
Subject(s) - myeloperoxidase , biology , mathematics , immunology , inflammation

The severity of cystic fibrosis (CF) pulmonary disease is not directly related to CFTR genotype but depends upon several parameters, including neutrophil-dominated inflammation. Identification of agents modulating inflammation constitutes a relevant goal. Myeloperoxidase (MPO) is involved in both microbicidal and proinflammatory neutrophil activities. The aim of this study was to evaluate whether the 463GA MPO promoter polymorphism is linked to clinical severity of CF-associated pulmonary inflammation. This polymorphism significantly affects the level of MPO gene expression in leukocytes and the G allele is more expressing than the A allele. We show that MPO genotype significantly influences the severity of pulmonary disease in early stages, prior to the development of chronic lung infections, with GG genotype being associated with more severe CF disease. Our findings indicate that the level of MPO gene expression influences the CF pathogenesis, presumably reflecting cellular damage by MPO-generated oxidants or other activity of MPO in airway inflammation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom